Back to News
Market Impact: 0.3
Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
Source: PR Newswire
Healthcare & BiotechProduct Launches
The global Phase III DEEp SEA trial of investigational bexicaserin has completed randomization in children and adults with Dravet syndrome. The milestone advances the broader Phase III DEEp development program evaluating the drug's efficacy, safety and tolerability, but no clinical efficacy data or regulatory timeline was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- SpaceX will try to put Starship in orbit for the first time on September 22
- A sharp stock market decline could lie around the corner, Wells Fargo warns